MARKET

FATE

FATE

Fate Therapeutic
NASDAQ
22.41
+0.07
+0.31%
After Hours: 22.41 0 0.00% 17:00 09/30 EDT
OPEN
22.35
PREV CLOSE
22.34
HIGH
23.82
LOW
22.30
VOLUME
1.12M
TURNOVER
0
52 WEEK HIGH
66.56
52 WEEK LOW
17.10
MARKET CAP
2.17B
P/E (TTM)
-8.4919
1D
5D
1M
3M
1Y
5Y
Tesla, Meta, NVIDIA And Other Big Losers From Tuesday
U.S. stocks closed sharply lower with the Nasdaq Composite dipping more than 5% on Tuesday. Here is the list of some big stocks moving lower in the previous session.
Benzinga · 09/14 09:54
Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $35
Morgan Stanley analyst Michael Ulz maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $45 to $35.
Benzinga · 09/09 12:51
--Morgan Stanley Cuts Price Target on Fate Therapeutics to $35 From $45, Maintains Equalweight Rating
--Morgan Stanley Cuts Price Target on Fate Therapeutics to $35 From $45, Maintains Equalweight Rating
MT Newswires · 09/09 09:01
Fate Therapeutics (FATE) Down 17% Since Last Earnings Report: Can It Rebound?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/02 15:31
Fate Therapeutics to Participate at Upcoming September Investor Conferences
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with ca...
GlobeNewswire · 09/02 12:00
Apple, Amazon, HP And Other Big Losers From Friday
U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.
Benzinga · 08/29 09:12
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.
Benzinga · 08/29 06:55
Fate Therapeutics gains as Wells Fargo cites upcoming catalysts
The shares of clinical-stage biotech Fate Therapeutics (NASDAQ:FATE</s...
Seekingalpha · 08/18 13:14
More
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of programmed cellular immunotherapies for patients with cancer. It uses human induced pluripotent stem cells (iPSCs) generated from its proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is advancing a pipeline of programmed cellular immunotherapies, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master iPSC lines for the treatment of cancer. The Company's product pipeline includes FT596, FT538, FT576, FT536, FT573, FT819, FT500 and FT516. FT516 is an investigational off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a novel CD16 (hnCD16) Fc receptor. FT596 is an investigational off-the-shelf CAR NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.

Webull offers kinds of Fate Therapeutics Inc stock information, including NASDAQ:FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.